title: The advancing clinical impact of molecular imaging in CVD.
abstract: Molecular imaging seeks to unravel critical molecular and cellular events in living subjects by providing complementary biological information to current structural clinical imaging modalities. In recent years, molecular imaging efforts have marched forward into the clinical cardiovascular arena, and are now actively illuminating new biology in a broad range of conditions, including atherosclerosis, myocardial infarction, thrombosis, vasculitis, aneurysm, cardiomyopathy, and valvular disease. Development of novel molecular imaging reporters is occurring for many clinical cardiovascular imaging modalities (positron emission tomography, single-photon emission computed tomography, magnetic resonance imaging), as well as in translational platforms such as intravascular fluorescence imaging. The ability to image, track, and quantify molecular biomarkers in organs not routinely amenable to biopsy (e.g., the heart and vasculature) open new clinical opportunities to tailor therapeutics based on a cardiovascular disease molecular profile. In addition, molecular imaging is playing an increasing role in atherosclerosis drug development in phase II clinical trials. Here, we present state-of-the-art clinical cardiovascular molecular imaging strategies, and explore promising translational approaches positioned for clinical testing in the near term.
authors: Cardiology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
authors: Eric A
authors: EA
authors: Osborn
authors: Cardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Center for Molecular Imaging Research and Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: fjaffer@mgh.harvard.edu.
authors: Farouc A
authors: FA
authors: Jaffer
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D006801:Humans; D057054:Molecular Imaging / Q000379:methods; D018579:Patient Selection; D011237:Predictive Value of Tests; D011379:Prognosis
chemical_list: D015415:Biomarkers
keywords: (158)Gd-ESMA; (18)F-fluorodeoxyglucose; (18)F-sodium fluoride; AS; AT1R; CAC; CEA; CMR; CT; DVT; FDA; FDG; Food and Drug Administration; ICG; LDL; LV; MI; MMP; MRI; NIRF; NaF; OFDI; OTW; PC; PET; RAAS; SUV; TBR; USPIO; aneurysm; angiotensin II type 1 receptor; aortic stenosis; atherosclerosis; cardiac magnetic resonance; carotid endarterectomy; computed tomography; coronary artery calcium; deep vein thrombosis; gadolinium-labeled elastin-specific magnetic resonance contrast agent; heart failure; high-sensitivity C-reactive protein; hsCRP; indocyanine green; left ventricle/ventricular; low-density lipoprotein; magnetic resonance imaging; matrix metalloproteinase; molecular imaging; myocardial infarction; near-infrared fluorescence; optical frequency domain imaging; over-the-wire; perfusion catheter; positron emission tomography; renin-angiotensin-aldosterone system; standardized uptake value; target-to-background ratio; thrombosis; ultrasmall superparamagnetic particles of iron oxide; valvular disease; vascular injury